Back to results
US 12,109,270 B2Granted
Rifaximin complexes
AssigneeCipla Limited
InventorsMaruti Ganpati Ghagare, Sunilkumar Parasnath Saroj, Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
Life of this patent
Estimating the term…
Abstract
There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.
Claims12
A method of treating bowel disorders, the method comprising:
- administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent, wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent.
A method of treating bowel disorders, the method comprising:
- administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent,
- wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent, the complex is a component of a tablet, and the rifaximin complex is administered with one or more pharmaceutically acceptable excipients.
A method of treating bowel disorders, the method comprising:
- administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent,
- wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent, the complex is a component of a tablet or a capsule, the bowel disorder is a bowel disease, and the rifaximin complex is administered with one or more pharmaceutically acceptable excipients.
A method of treating bowel disorders, the method comprising:
- administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent,
- wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent, the complex is a component of a tablet or a capsule, the bowel disorder is microbe associated diarrhea, and the rifaximin complex is administered with one or more pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.